# Osteocytic vinculin controls bone mass by modulating Mef2c-driven sclerostin expression in mice

**Authors:** Yishu Wang, Jianmei Huang, Sixiong Lin, Lei Qin, Dingyu Hao, Peijun Zhang, Shaochuan Huo, Xuenong Zou, Di Chen, Guozhi Xiao

PMC · DOI: 10.1038/s41413-025-00452-x · 2025-08-13

## TL;DR

This study shows that vinculin in osteocytes controls bone mass by regulating sclerostin expression, offering new insights into osteoporosis.

## Contribution

The paper identifies a novel mechanism where vinculin inhibits Mef2c-driven sclerostin expression in osteocytes to promote bone formation.

## Key findings

- Vinculin loss in osteocytes impairs adhesion and dendrite formation, leading to bone loss in mice.
- Vinculin interacts with Mef2c to regulate sclerostin expression, affecting bone formation.
- Deleting Sost in osteocytes reverses bone loss caused by vinculin deficiency.

## Abstract

The focal adhesion (FA) is the structural basis of the cell-extracellular matrix crosstalk and plays important roles in control of organ formation and function. Here we show that expression of FA protein vinculin is dramatically reduced in osteocytes in patients with aging-related osteoporosis. Vinculin loss severely impaired osteocyte adhesion and dendrite formation. Deleting vinculin using the mouse 10-kb Dmp1-Cre transgenic mice causes dramatic bone loss in the weight-bearing long bones and spine, but not in the skull, in both young and aged mice by impairing osteoblast formation and function without markedly affecting bone resorption. Vinculin loss impairs the anabolic response of skeleton to mechanical loading in mice. Vinculin knockdown increases, while vinculin overexpression decreases, sclerostin expression in osteocytes without impacting expression of Mef2c, a major transcriptional regulator of the Sost gene, which encodes sclerostin. Vinculin interacts with Mef2c and retains the latter in the cytoplasm. Thus, vinculin loss enhances Mef2c nuclear translocation and binding to the Sost enhancer ECR5 to promote sclerostin expression in osteocytes and reduces bone formation. Consistent with this notion, deleting Sost expression in osteocytes reverses the osteopenic phenotypes caused by vinculin loss in mice. Finally, we find that estrogen is a novel regulator of vinculin expression in osteocytes and that vinculin-deficient mice are resistant to ovariectomy-induced bone loss. Thus, we demonstrate a novel mechanism through which vinculin inhibits the Mef2c-driven sclerostin expression in osteocytes to promote bone formation.

## Linked entities

- **Genes:** LOC110462068 (vinculin-like) [NCBI Gene 110462068], MEF2C (myocyte enhancer factor 2C) [NCBI Gene 4208], SOST (sclerostin) [NCBI Gene 50964]
- **Proteins:** LOC110462068 (vinculin-like), MEF2C (myocyte enhancer factor 2C)
- **Diseases:** osteoporosis (MONDO:0005298)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Vcl (vinculin) [NCBI Gene 22330] {aka 9430097D22}, Sost (sclerostin) [NCBI Gene 74499] {aka 5430411E23Rik}, Mef2c (myocyte enhancer factor 2C) [NCBI Gene 17260] {aka 5430401D19Rik, 9930028G15Rik, Mef2}, Dmp1 (dentin matrix protein 1) [NCBI Gene 13406] {aka AG1, DMP-1, Dmp, PP}
- **Diseases:** osteoporosis (MESH:D010024), osteopenic (MESH:C567172), bone loss (MESH:D001847)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12343990/full.md

---
Source: https://tomesphere.com/paper/PMC12343990